Selank (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulator tuftsin and studied for its anxiolytic and neurobehavioral activity. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 4.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration, every 0.02 mL drawn on a U-100 insulin syringe equals 2 units and delivers 100 mcg of material, which keeps the arithmetic clean across the daily microgram-scale steps used for this peptide.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the conservative introduction used in the research literature, where daily microgram amounts were stepped up over the first weeks to establish tolerability before settling at a maintenance level.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 4.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Higher-Dose) Schedule

Some research protocols push the daily amount toward the upper end of the studied band for short courses. This schedule reaches a 750 mcg ceiling and otherwise keeps the same once-daily cadence.

Supplies Needed

• Selank vials (20 mg): ~1 vial covers a 6-week 500 mcg/day course; ~2 vials for a 16-week run at 500 mcg/day; ~3 vials for a 16-week run at 750 mcg/day.
• Insulin syringes (U-100, 1 mL): roughly one per daily dose — about 42 for a 6-week course, ~112 for a 16-week daily course.
• Bacteriostatic water (10 mL): one bottle covers two 20 mg vials with diluent to spare.
• Alcohol swabs: a 100-count box covers about six weeks of daily handling; budget 2–3 boxes for a 16-week course.

Protocol Overview

• Research goal: model anxiolytic, anti-asthenic and neuromodulatory activity via a tuftsin-derived heptapeptide.
• Schedule: once-daily administration in the published model (some designs use 5 days on, 2 days off).
• Dose band: 300–500 mcg/day standard, up to 750 mcg/day in higher-dose arms.
• Fill: 20 mg lyophilized, reconstituted to 5 mg/mL with 4 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 300 mcg step and hold for the first two weeks before moving to the maintenance level.
• Keep administration on a fixed daily cadence and the same time of day where possible for steady exposure modelling.
• Because the peptide is short-acting, some research designs split the daily amount across morning and afternoon draws.
• Center most courses on the 500 mcg/day maintenance band, which carries the bulk of the published signal.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about four weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• The 5 mg/mL fill keeps even the 750 mcg step under 0.15 mL, so no dose requires splitting.
• Document each draw — date, volume, remaining material — for reproducibility.

How Selank Works

Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide, extended and stabilized to slow enzymatic breakdown. Research attributes its anxiolytic profile to modulation of monoamine and GABAergic signalling, alongside shifts in the expression of brain-derived neurotrophic factor and effects on enkephalin-degrading enzymes that prolong endogenous regulatory peptide activity. Unlike benzodiazepines, the published model reports calming activity without sedation, motor impairment or dependence, which is why research designs allow daytime administration.

Reported Benefits & Side Effects

Benefits observed in research

• Anxiolytic activity reported as comparable to benzodiazepines but without sedation.
• Anti-asthenic (energy-supporting) effects in the published trials.
• Stabilizing neurobehavioral effects observed over longer courses.
• Daytime administration without measurable cognitive or motor impairment.

Side effects reported

• Occasional mild injection-site reactions — transient redness or minor irritation — with subcutaneous use.
• Site rotation reduced the frequency of local reactions.
• Generally well tolerated across the studied dose band with no dependence signal.

Supporting Lifestyle Factors (Research Context)

• Consistent sleep and structured stress-management routines as standard study controls.
• Stable daily timing of administration to model steady neuropeptide exposure.
• Adequate hydration and balanced nutrition alongside the dosing window.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Volumes here are small (≤0.15 mL), so a single site per dose is sufficient.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols